Rheumnow Podcast cover image

EULAR 2023 Lupus Highlights

Rheumnow Podcast

00:00

ABBV59.9 High Dose in SLE

Yusuf Yusuf is reporting from Milan for ULA 2023 Congress. Today, he will discuss the abstract number OP 0139 about a new therapy in SLE. This is a phase two randomized control trial of a compound called ABBV59.9 high dose,. It's actually a combination of a BTK inhibitor called also Bruteinib and Upada Sitinib which is a JAC1 inhibitors.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app